The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer

Bhatt, Aditi; Gléhen, Olivier; Zivanovic, Oliver; Brennan, Donal J.; Nadeau, C.; Driel, Willemien J. van; Bakrin, Naoual

doi:10.1245/s10434-023-13932-3

Cited by 8 publications

(3 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The collective evidence from these studies is reflected in the current clinical guidelines, which, as of the latest consensus, do not uniformly endorse HIPEC in conjunction with primary or secondary CRS. However, opinions on the integration of HIPEC with interval CRS range from supportive to not recommended among various global societies and organizations [ 13 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Gęca,

Litwiński,

Ostrowski

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Recurrent ovarian cancer (ROC) significantly challenges gynecological oncology due to its poor outcomes. This study assesses the impact of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on ROC survival rates. Materials and Methods: Conducted at the Medical University of Lublin from April 2011 to November 2022, this retrospective observational study involved 71 patients with histologically confirmed ROC who underwent CRS and subsequent HIPEC. Results: The median overall survival (OS) was 41.1 months, with 3-year and 5-year survival rates post-treatment of 0.50 and 0.33, respectively. Patients undergoing radical surgery for primary ovarian cancer had a median OS of 61.9 months. The key survival-related factors included the Peritoneal Carcinomatosis Index (PCI) score, AGO score, platinum sensitivity, and ECOG status. Conclusions: The key factors enhancing ROC patients’ survival include radical surgery, optimal performance status, platinum sensitivity, a positive AGO score, and a lower PCI. This study highlights the predictive value of the platinum resistance and AGO score in patient outcomes, underlining their role in treatment planning. Further prospective research is needed to confirm these results and improve patient selection for this treatment approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Gęca,

Litwiński,

Ostrowski

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have transitioned from being niche procedures offered by a select group of dedicated surgeons and institutions to becoming globally accessible techniques. The trend towards standardization, exemplified by collaborative efforts such as the study by Bhatt et al, (1) has ushered in a new era in the treatment landscape. Over the past two decades, the number of CRS/HIPEC-performing surgeons has significantly increased worldwide.…”

Section: Editorial On the Research Topicmentioning

confidence: 99%

“…The trend towards standardization, exemplified by collaborative efforts such as the study by Bhatt et al. , ( 1 ) has ushered in a new era in the treatment landscape. Over the past two decades, the number of CRS/HIPEC-performing surgeons has significantly increased worldwide.…”

mentioning

confidence: 99%

Editorial: Management of peritoneal surface malignancies. (cytoreductive surgery, HIPEC, PIPAC, and beyond)

Souadka,

Bakrin

2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Review of 2022 PSOGI/RENAPE Consensus on HIPEC

Kusamura,

Bhatt,

van Der Speeten

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

The 2022 PSOGI (Peritoneal Surface Oncology Group International) and RENAPE (French Network for Rare Peritoneal Malignancies) consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) was a comprehensive effort aimed at standardizing treatment protocols for various peritoneal malignancies. This initiative is critical due to the wide range of technical variations in HIPEC procedures and the resulting need for standardization to ensure consistent and effective patient care and meaningful audit of multicenter data.

show abstract

The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer

Cited by 8 publications

References 107 publications

Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Editorial: Management of peritoneal surface malignancies. (cytoreductive surgery, HIPEC, PIPAC, and beyond)

Review of 2022 PSOGI/RENAPE Consensus on HIPEC

Contact Info

Product

Resources

About